NCT00022672View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

January 31, 2001

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Breast Cancer
Interventions
DRUG

trastuzumab (Herceptin®)

4mg/kg iv loading dose, followed by 2mg/kg iv weekly

DRUG

anastrazole (Arimidex®)

1 mg tablet taken orally daily

Trial Locations (132)

112

Taipei

333

Taoyuan District

1527

Sofia

1715

Floracliffe

2010

Darlinghurst

2298

Waratah

2600

Vilnius

3128

Box Hill

4000

Plovdiv

7006

Trondheim

8000

Stara Zagora

14000

Mexico City

14004

Córdoba

14642

Rochester

16132

Genova

17007

Girona

17176

Stockholm

24105

Kiel

28007

Madrid

28034

Madrid

28041

Madrid

31096

Haifa

32605

Gainsville

33176

Miami

33324

Plantation

34300

Istanbul

34362

Haifa

34390

Istanbul

35100

Izmir

40005

Sumy

43204

Reus

44106

Cleveland

44340

Guadalajara

46009

Valencia

49100

Petah Tikva

50182

Borås

52621

Ramat Gan

54290

Trier

60596

Frankfurt

60612

Chicago

60637

Chicago

64239

Tel Aviv

65055

Odesa

66160

Kansas City

68114

Omaha

69104

Zaporizhzhya

76100

Rehovot

79031

Lviv

80187

Gaelve

80637

München

84082

Avignon

85006

Phoenix

87505

Santa Fe

90048

Los Angeles

94589

Vallejo

100021

Beijing

100071

Beijing

107005

Moscow

110085

New Delhi

115478

Moscow

117837

Moscow

121356

Moscow

125284

Moscow

189646

Saint Petersburg

197022

Saint Petersburg

197758

Saint Petersburg

200025

Shanghai

200032

Shanghai

350080

Krasnodar

400012

Mumbai

420029

Kazan'

426009

Izhevsk

430030

Wuhan

450054

Ufa

656049

Barnaul

72205-7199

Little Rock

04074

Scarborough

48202-2689

Detroit

07601

Hackensack

87131-5636

Albuquerque

45267-0562

Cincinnati

17033-0850

Hershey

90610-000

Porto Alegre

T2N 4N2

Calgary

T6G 1Z2

Edmonton

V8R 6V5

Victoria

R3E 0V9

Winnipeg

L1G 2B9

Oshawa

M4N 3M5

Toronto

M5G 2M9

Toronto

H1T 2M4

Montreal

G1S 4L8

Québec

06189

Nice

Unknown

Hong Kong

Pretoria

Kiev

H-1122

Budapest

380 016

Ahmedabad

560 029

Bangalore

600 020

Chennai

753 007

Cuttack

141 001

Ludhiana

110 029

New Delhi

110 060

New Delhi

1081 HV

Amsterdam

3075 EA

Rotterdam

15-027

Bialystok

85-796

Bydgoszcz

44-101

Gliwice

31-115

Krakow

94-306

Lodz

71-730

Szczecin

00-909

Warsaw

02-781

Warsaw

08036

Barcelona

08304

Mataró

701 85

Örebro

06230

Ankara

06500

Ankara

06100

Shhiye, Ankara

03022

Kiev

CF14 2TL

Cardiff

EH4 2XU

Edinburgh

GU2 7XX

Guildford

IP4 5PD

Ipswich

NW3 2QG

London

SE1 9RT

London

M20 4BX

Manchester

CH63 45Y

Merseyside

NE4 6BE

Newcastle upon Tyne

SO16 6YD

Southampton

SA2 8QA

Swansea

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Hoffmann-La Roche

INDUSTRY